Richard Davidson, Sarcoma UK Chief Executive
Friday, January 18, 2019

Sarcoma UK is really disappointed to read the outcome of ANNOUNCE, a Phase 3 trial of the drug LARTRUVO® (also known as olaratumab) from the pharmaceutical company Lilly.

Eli Lilly and Company announced today that the results of the trial 'did not confirm the clinical benefit of LARTRUVO in combination with doxorubicin', when treating advanced soft tissue sarcoma. You can read the full announcement from Lilly here.  

We are keeping abreast of the situation and will update you as soon as we know more about what this means for sarcoma patients. You can also stay up to date with developments about this through our Twitter feed (@Sarcoma_UK).